Previous Article | Next Article ![]()
Journal of Clinical Microbiology, August 1999, p. 2564-2567, Vol. 37, No. 8
Center for Biologics Evaluation and Research,
Food and Drug Administration, Bethesda,
Maryland,1 and Departments of
Laboratory Medicine and Pathology and Pediatrics, University of
Minnesota Medical School, Minneapolis,
Minnesota2
Received 30 March 1999/Returned for modification 4 May
1999/Accepted 18 May 1999
Group B Streptococcus (GBS) is one of the most common organisms
causing neonatal sepsis as well as serious infections in adults. Serotyping the organism is important in studying the epidemiology of
the disease as well as deciding a course of treatment. There are
several methods available for serotyping. Most of them need high-titered sera and are not quantitative. We are reporting a new
inhibition enzyme-linked immunosorbent assay (ELISA) for serotyping which is sensitive and specific compared to the conventional methods but does not need high-titered serotype-specific antisera, as the
specificity is controlled by the polysaccharide coating on the ELISA
plates. The method can also be quantitative, and we have measured
polysaccharide elaborated by different serotype V strains. Thus, the
inhibition ELISA method will be useful in serotyping for
epidemiological studies, assessing virulence, and performing strain
selection for vaccine production.
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Inhibition Enzyme-Linked Immunosorbent Assay for
Serotyping of Group B Streptococcal Isolates
*
Corresponding author. Mailing address: Division of
Bacterial Products, Center for Biologics Evaluation and Research, 1401 Rockville Pike, Mailstop HFM-428, Rockville, MD 20853. Phone: (301)
496-9173. Fax: (301) 402-2776. E-mail:
arakereg{at}cber.fda.gov.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»